Clinical Trial Update: Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports that the Tocilizumab study in patients with Hepatocellular Carcinoma undergoing transarterial chemoembolization has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN